Salem Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $255K | Hold |
1,900
| – | – | 0.2% | 50 |
|
|
2022
Q2 | $291K | Hold |
1,900
| – | – | 0.21% | 50 |
|
|
2022
Q1 | $308K | Hold |
1,900
| – | – | 0.17% | 56 |
|
|
2021
Q4 | $257K | Hold |
1,900
| – | – | 0.13% | 64 |
|
|
2021
Q3 | $205K | Hold |
1,900
| – | – | 0.11% | 71 |
|
|
2021
Q2 | $214K | Hold |
1,900
| – | – | 0.12% | 75 |
|
|
2021
Q1 | $206K | Sell |
1,900
-1,600
| -46% | -$171K | 0.12% | 72 |
|
|
2020
Q4 | $375K | Hold |
3,500
| – | – | 0.24% | 54 |
|
|
2020
Q3 | $307K | Hold |
3,500
| – | – | 0.22% | 55 |
|
|
2020
Q2 | $344K | Hold |
3,500
| – | – | 0.25% | 53 |
|
|
2020
Q1 | $267K | Hold |
3,500
| – | – | 0.22% | 57 |
|
|
2019
Q4 | $310K | Hold |
3,500
| – | – | 0.17% | 57 |
|
|
2019
Q3 | $265K | Sell |
3,500
-550
| -14% | -$37.7K | 0.15% | 63 |
|
|
2019
Q2 | $295K | Hold |
4,050
| – | – | 0.16% | 61 |
|
|
2019
Q1 | $326K | Sell |
4,050
-1,675
| -29% | -$137K | 0.18% | 59 |
|
|
2018
Q4 | $528K | Hold |
5,725
| – | – | 0.33% | 50 |
|
|
2018
Q3 | $541K | Hold |
5,725
| – | – | 0.29% | 49 |
|
|
2018
Q2 | $530K | Hold |
5,725
| – | – | 0.28% | 50 |
|
|
2018
Q1 | $542K | Sell |
5,725
-2,275
| -28% | -$250K | 0.29% | 50 |
|
|
2017
Q4 | $774K | Sell |
8,000
-3,700
| -32% | -$349K | 0.39% | 46 |
|
|
2017
Q3 | $1.04M | Sell |
11,700
-600
| -5% | -$45.7K | 0.54% | 41 |
|
|
2017
Q2 | $892K | Sell |
12,300
-300
| -2% | -$20.2K | 0.5% | 43 |
|
|
2017
Q1 | $821K | Sell |
12,600
-1,950
| -13% | -$123K | 0.46% | 43 |
|
|
2016
Q4 | $911K | Sell |
14,550
-600
| -4% | -$36.6K | 0.5% | 43 |
|
|
2016
Q3 | $956K | Hold |
15,150
| – | – | 0.52% | 44 |
|
|
2016
Q2 | $938K | Sell |
15,150
-15,100
| -50% | -$920K | 0.54% | 42 |
|
|
2016
Q1 | $1.73M | Sell |
30,250
-900
| -3% | -$50.2K | 0.97% | 31 |
|
|
2015
Q4 | $1.84M | Sell |
31,150
-1,525
| -5% | -$87.8K | 1.04% | 31 |
|
|
2015
Q3 | $1.78M | Sell |
32,675
-1,325
| -4% | -$86.2K | 1.04% | 31 |
|
|
2015
Q2 | $2.28M | Buy |
34,000
+300
| +0.9% | +$19.6K | 1.18% | 29 |
|
|
2015
Q1 | $1.97M | Sell |
33,700
-1,000
| -3% | -$60.4K | 1% | 31 |
|
|
2014
Q4 | $2.27M | Sell |
34,700
-9,650
| -22% | -$608K | 1.08% | 32 |
|
|
2014
Q3 | $2.56M | Sell |
44,350
-2,200
| -5% | -$122K | 1.19% | 32 |
|
|
2014
Q2 | $2.63M | Sell |
46,550
-3,025
| -6% | -$159K | 1.17% | 33 |
|
|
2014
Q1 | $2.55M | Sell |
49,575
-6,850
| -12% | -$346K | 1.12% | 34 |
|
|
2013
Q4 | $2.98M | Buy |
56,425
+675
| +1% | +$33.2K | 1.29% | 34 |
|
|
2013
Q3 | $2.49M | Sell |
55,750
-8,600
| -13% | -$381K | 1.15% | 35 |
|
|
2013
Q2 | $2.66M | Buy |
+64,350
| New | +$2.81M | 1.27% | 35 |
|
Other funds holding ABBV
Salem Capital Management's ABBV Position: Q3 2022 in Review
Salem Capital Management held its AbbVie (ABBV) position steady in Q3 2022 at 1,900 shares worth $255K. The position accounts for 0.2% of the portfolio, ranked #50.
Salem Capital Management first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.98M in Q4 2013. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- Salem Capital Management held 1,900 shares of AbbVie worth $255K as of Q3 2022.
- Salem Capital Management left its AbbVie share count unchanged in Q3 2022.
- AbbVie made up 0.2% of Salem Capital Management's portfolio in Q3 2022, its #50 holding.
- Salem Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Salem Capital Management's AbbVie position peaked at $2.98M in Q4 2013.
- 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on Salem Capital Management's 13F filing for Q3 2022, filed 29 Nov 2022.